These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 24919864)

  • 41. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
    Nash P; Kirkham B; Okada M; Rahman P; Combe B; Burmester GR; Adams DH; Kerr L; Lee C; Shuler CL; Genovese M;
    Lancet; 2017 Jun; 389(10086):2317-2327. PubMed ID: 28551073
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
    Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
    Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Update on the treatment of peripheral arthritis in psoriatic arthritis.
    Soriano ER; Rosa J
    Curr Rheumatol Rep; 2009 Aug; 11(4):270-7. PubMed ID: 19691930
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.
    Culy CR; Keating GM
    Drugs; 2002; 62(17):2493-537. PubMed ID: 12421111
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Clinical and Cost Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis: A Critique of the Evidence.
    O'Connor J; Rice S; Smith A; Rodgers M; Lopez RR; Craig D; Woolacott N
    Pharmacoeconomics; 2016 Apr; 34(4):337-48. PubMed ID: 26818809
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Keating GM
    Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of systemic treatments in psoriatic arthritis: a systematic review, meta-analysis and GRADE evaluation.
    Dressler C; Eisert L; Pham PA; Nast A
    J Eur Acad Dermatol Venereol; 2019 Jul; 33(7):1249-1260. PubMed ID: 30735612
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study.
    Araujo EG; Englbrecht M; Hoepken S; Finzel S; Kampylafka E; Kleyer A; Bayat S; Schoenau V; Hueber A; Rech J; Schett G
    Semin Arthritis Rheum; 2019 Feb; 48(4):632-637. PubMed ID: 30037432
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis.
    Lee MP; Desai RJ; Jin Y; Brill G; Ogdie A; Kim SC
    JAMA Dermatol; 2019 Jun; 155(6):700-707. PubMed ID: 30916734
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risankizumab in Adults with Psoriatic Arthritis.
    Machlab K; Yeung J; Gooderham M
    Skin Therapy Lett; 2023 Nov; 28(6):1-6. PubMed ID: 38015960
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ustekinumab for the treatment of psoriatic arthritis.
    Chandler DJ; Bewley A
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):111-21. PubMed ID: 24494794
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Emerging drugs for psoriatic arthritis.
    Caso F; Del Puente A; Peluso R; Caso P; Girolimetto N; Del Puente A; Scarpa R; Costa L
    Expert Opin Emerg Drugs; 2016; 21(1):69-79. PubMed ID: 26807876
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE).
    Iannone F; Santo L; Bucci R; Semeraro A; Carlino G; Paoletti F; Quarta L; Leucci P; Zuccaro C; Marsico A; Scioscia C; D'Onofrio F; Mazzotta D; Muratore M; Cantatore FP; Lapadula G
    Clin Rheumatol; 2018 Mar; 37(3):667-675. PubMed ID: 29411182
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Apremilast for the treatment of psoriatic arthritis.
    Souto A; Gómez-Reino JJ
    Expert Rev Clin Immunol; 2015; 11(12):1281-90. PubMed ID: 26503917
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
    Genovese MC; Mease PJ; Thomson GT; Kivitz AJ; Perdok RJ; Weinberg MA; Medich J; Sasso EH;
    J Rheumatol; 2007 May; 34(5):1040-50. PubMed ID: 17444593
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Golimumab for the treatment of psoriatic arthritis.
    Yang H; Epstein D; Bojke L; Craig D; Light K; Bruce I; Sculpher M; Woolacott N
    Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.
    Langley RG; Armstrong AW; Lebwohl MG; Blauvelt A; Hsu S; Tyring S; Rastogi S; Pillai R; Israel R
    Br J Dermatol; 2019 Feb; 180(2):306-314. PubMed ID: 30328108
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review.
    Thibodaux RJ; Triche MW; Espinoza LR
    Expert Opin Biol Ther; 2018 Jul; 18(7):821-827. PubMed ID: 29949399
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials.
    McInnes IB; Puig L; Gottlieb AB; Ritchlin CT; Song M; You Y; Kafka S; Morgan GJ; Rahman P; Kavanaugh A;
    J Rheumatol; 2019 Nov; 46(11):1458-1461. PubMed ID: 30936281
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
    Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.